Immunocore Holdings plc (IMCR)

NASDAQ: IMCR · IEX Real-Time Price · USD
38.46
-1.23 (-3.10%)
At close: Jun 14, 2024, 4:00 PM
39.48
+1.02 (2.65%)
After-hours: Jun 14, 2024, 6:06 PM EDT
-3.10%
Market Cap 1.92B
Revenue (ttm) 264.25M
Net Income (ttm) -58.85M
Shares Out 50.01M
EPS (ttm) -1.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 483,422
Open 39.44
Previous Close 39.69
Day's Range 38.21 - 39.44
52-Week Range 38.21 - 76.98
Beta 0.83
Analysts Strong Buy
Price Target 82.77 (+115.21%)
Earnings Date Aug 8, 2024

About IMCR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 497
Stock Exchange NASDAQ
Ticker Symbol IMCR
Full Company Profile

Financial Performance

In 2023, IMCR's revenue was 249.43 million, an increase of 43.05% compared to the previous year's 174.36 million. Losses were -55.29 million, 5.22% more than in 2022.

Financial numbers in GBP Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for IMCR stock is "Strong Buy." The 12-month stock price forecast is $82.77, which is an increase of 115.21% from the latest price.

Price Target
$82.77
(115.21% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

14 days ago - GlobeNewsWire

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

15 days ago - GlobeNewsWire

Immunocore to present at the Jefferies Global Healthcare Conference

Immunocore to present at the Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.

16 days ago - GlobeNewsWire

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

17 days ago - GlobeNewsWire

Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.

The American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual meeting. Companies such as GSK, Moderna, BioNTech, Gilead, and many others will reporting their progress.

Other symbols: GILDMRNA
22 days ago - Barrons

Immunocore reports first quarter financial results and provides a business update

Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 addi...

5 weeks ago - GlobeNewsWire

Immunocore announces upcoming presentation and posters at ASCO 2024

Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presen...

7 weeks ago - GlobeNewsWire

Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.

2 months ago - GlobeNewsWire

Immunocore presented two posters at CROI 2024

Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.

3 months ago - GlobeNewsWire

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023; increa...

3 months ago - GlobeNewsWire

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first...

4 months ago - GlobeNewsWire

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.

4 months ago - GlobeNewsWire

Immunocore Prices Upsized Convertible Senior Notes Offering

Immunocore Prices Upsized Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, January 30, 2024) Immunocore Holdings plc (Nasdaq: IMCR) today announced the pr...

4 months ago - GlobeNewsWire

Immunocore Announces Proposed Convertible Senior Notes Offering

Immunocore Announces Proposed Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, January 29, 2024) Immunocore Holdings plc (Nasdaq: IMCR), today announced i...

4 months ago - GlobeNewsWire

Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation

Immunocore announces strategic priorities and pipeline expansion ahead of 42 nd Annual J.P. Morgan Healthcare Conference presentation

5 months ago - GlobeNewsWire

Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference

Immunocore to present at the 42 nd Annual J.P. Morgan Healthcare Conference

5 months ago - GlobeNewsWire

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major markets wit...

7 months ago - GlobeNewsWire

Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 01 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel cl...

8 months ago - GlobeNewsWire

Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial

Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023

8 months ago - GlobeNewsWire

Immunocore announces upcoming presentation and posters at ESMO 2023

Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a late-break...

9 months ago - GlobeNewsWire

Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update

Immunocore Reports Second Quarter 202 3 Financial Results and Provides Business Update KIMMTRAK net revenues of £ 45 . 5 million ($ 57.8 million) in 2 Q 2023 ; new launches in Italy , Austria , Finlan...

11 months ago - GlobeNewsWire

Immunocore to report second quarter 2023 financial results and host call on August 10, 2023

Immunocore to report second quarter 2023 financial results and host call on August 10, 2023

11 months ago - GlobeNewsWire

Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO

Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival

1 year ago - GlobeNewsWire

Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update

Immunocore Reports First Quarter 202 3 Financial Results and Provides Business Update

1 year ago - GlobeNewsWire

Immunocore to present at the Bank of America Securities 2023 Health Care Conference

Immunocore to present at the Bank of America Securities 2023 Health C are Conference

1 year ago - GlobeNewsWire